La TM (telemedicina) podría ayudar en el tratamiento de la EPOC, pero aún queda un largo camino para poder implantar un sistema seguro a nivel nacional.
Descubre las innovaciones presentadas en el 57º Congreso SEPAR 2024. El Dr. Alvar Agustí, Catedrático de la Cátedra De Salud Respiratoria de la UB moderó: Aire de debate. Novedades en EPOC 2024
Explore how systemic inflammation differs between brain-dead (DBD) and circulatory-dead (DCD) lung donors and its impact on primary graft dysfunction (PGD) and mortality in lung transplant recipients.
Explore the link between Preserved Ratio Impaired Spirometry (PRISm) and arterial stiffness, highlighting significant findings from the Austrian LEAD study. Learn how PRISm impacts cardiovascular health.
Discover the relationships between symptoms and lung function in asthma and COPD from the NOVELTY study, highlighting key spirometry measures and their impact.
Aspergillus-associated disorders in bronchiectasis, based on data from the EMBARC Registry. ABPA, AS, and AB: Impact on disease severity, diagnostic criteria efficacy, etc.
Marked differences in peripheral blood immune cell gene expression were observed between bronchiectasis patients and healthy controls.
Transcriptomic changes were associated with disease severity and airway inflammation identifying potential novel biomarkers and therapeutic targets.
Video completo de la Primera Edición de REPRIMARIA de 8 del Mayo 2024
Some patients develop post-COVID organizing pneumonia (OP), which is responsiveto treatment with corticosteroids.
The efficacy and safety of mepolizumab in patients with COPD has been investigated in two placebo-controlled Phase 3 trials, METREX and METREO, and theongoing MATINEE trial.
